Instead of creating affordable products that improve health and lower costs, pharmaceutical companies focus on new drugs that will yield a healthy return on investment.

Excellergy is developing medicines that combat allergic responses in three different ways, a multipronged effect the company ...

Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing ...

The FDA named the first nine products to undergo a new expedited review process that takes 1 to 2 months, the agency ...

Dianthus Therapeutics (NASDAQ:DNTH) announced a licensing deal worth up to $1B with Nanjing Leads Biolabs on Thursday to ...

Among the flurry of executive orders (EOs) issued by President Trump as his first hundred days in office drew to a close are two taking aim at the high cost of prescription drugs. For many ideas in ...

Every hospital shelf and pharmacy counter depends on an invisible global current, the pharmaceutical supply chain. Yet this ...

The U.S. Food and Drug Administration (FDA) approved sotatercept in March 2024 for treatment of pulmonary hypertension, ...

This article outlines common CMC problems that are obstacles that steal momentum and create costly detours in the development ...

Shares of Apogee Therapeutics have gained 34% over the past two days as the small biotech looks to take on Regeneron and ...

While a new facility setup program aimed at encouraging onshoring received a positive reception at a recent meeting, industry ...

Although TrumpRx may provide some relief from high drug prices, its practical impact is limited, especially for expensive biologics and specialty drugs, as it does not include health plan coverage, ...